FDA warned Independent Seafoods Panama over missing written seafood safety plans for fresh and histamine fish.
What happened
FDA inspected the seafood processing facility on June 12–13, 2023, and issued a Form FDA-483, a list of inspection observations. FDA found the firm had no HACCP plan (a written seafood hazard-control plan) for grouper, snapper, and amberjack (ciguatera), for scombrotoxin-forming fish such as yellowfin tuna, mahimahi, mackerel, and amberjack (histamine), or for vacuum-packaged mahimahi fillets and stingray wings (Clostridium botulinum); its hazard analyses identified hazards but did not set critical control points.
What FDA found
The firm did not have a HACCP plan for grouper, snapper, and amberjack, which may cause ciguatera fish poisoning.
21 CFR 123.6(a) and (b)The firm did not have a HACCP plan for scombrotoxin-forming fish such as yellowfin tuna, mahimahi, mackerel, and amberjack, which may form histamine.
21 CFR 123.6(a) and (b)The firm did not have a HACCP plan for vacuum-packaged mahimahi fillets and stingray wings, which may allow Clostridium botulinum toxin formation.
21 CFR 123.6(a) and (b)The firm's hazard analyses identified pathogens and chemical residues as reasonably likely hazards but did not treat any processing step as a critical control point.
21 CFR 123.6(a) and (b)
What FDA wants
FDA asks the firm to respond in writing within 15 working days with the specific corrections, including revised hazard analyses and HACCP plans for every type of fish and 5 consecutive days of completed monitoring records for 5 production date codes. If the firm cannot complete all corrections in that time, it must explain the delay and state when it will finish.
Who should pay attention
- U.S. importers of Panamanian seafood
- brands and distributors selling fresh or histamine fish products
- seafood processors using hazard analyses without critical control points
This is a summary. Read the original letter on fda.gov.